Last reviewed · How we verify
Rectal cancer with wild-type RAS
Approved treatments
- Erbitux · Imclone
Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division. - Erbitux · Hellenic Oncology Research Group
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Rectal cancer with wild-type RAS patent landscape — cliff calendar, originator estates, attackable patents
- Rectal cancer with wild-type RAS treatment landscape brief
- Rectal cancer with wild-type RAS treatment updates RSS
Frequently asked questions about Rectal cancer with wild-type RAS
What drugs treat Rectal cancer with wild-type RAS?
Tracked treatments include Erbitux.
What is the treatment for Rectal cancer with wild-type RAS?
Standard treatment for Rectal cancer with wild-type RAS includes Erbitux. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Rectal cancer with wild-type RAS patent cliff · Rectal cancer with wild-type RAS CI report
- Treatment: Erbitux · Imclone
- Treatment: Erbitux · Hellenic Oncology Research Group
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing